HRP20120092T1 - Injektibilna smjesa za lumen mekog tkiva - Google Patents
Injektibilna smjesa za lumen mekog tkiva Download PDFInfo
- Publication number
- HRP20120092T1 HRP20120092T1 HR20120092T HRP20120092T HRP20120092T1 HR P20120092 T1 HRP20120092 T1 HR P20120092T1 HR 20120092 T HR20120092 T HR 20120092T HR P20120092 T HRP20120092 T HR P20120092T HR P20120092 T1 HRP20120092 T1 HR P20120092T1
- Authority
- HR
- Croatia
- Prior art keywords
- mixture
- agents
- microparticles
- component
- growth factor
- Prior art date
Links
- 239000000945 filler Substances 0.000 title claims abstract 4
- 210000004872 soft tissue Anatomy 0.000 title claims abstract 4
- 239000011800 void material Substances 0.000 title abstract 3
- 230000003416 augmentation Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract 30
- 239000004014 plasticizer Substances 0.000 claims abstract 4
- 239000002245 particle Substances 0.000 claims abstract 3
- 239000011859 microparticle Substances 0.000 claims 10
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 239000002872 contrast media Substances 0.000 claims 6
- 108010049003 Fibrinogen Proteins 0.000 claims 5
- 102000008946 Fibrinogen Human genes 0.000 claims 5
- 229940012952 fibrinogen Drugs 0.000 claims 5
- -1 bismuth thiols Chemical class 0.000 claims 4
- 239000001506 calcium phosphate Substances 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 229910000389 calcium phosphate Inorganic materials 0.000 claims 3
- 235000011010 calcium phosphates Nutrition 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 claims 2
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 claims 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims 2
- 102000015336 Nerve Growth Factor Human genes 0.000 claims 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940127219 anticoagulant drug Drugs 0.000 claims 2
- 229940112869 bone morphogenetic protein Drugs 0.000 claims 2
- 239000011575 calcium Substances 0.000 claims 2
- 229910052791 calcium Inorganic materials 0.000 claims 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 231100000599 cytotoxic agent Toxicity 0.000 claims 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims 2
- 229940053128 nerve growth factor Drugs 0.000 claims 2
- 150000002894 organic compounds Chemical group 0.000 claims 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims 2
- 229920001184 polypeptide Polymers 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 claims 1
- RHISTIGVAKTTCM-UHFFFAOYSA-N 5-[[3-[3,5-bis(1,3-dihydroxypropan-2-ylcarbamoyl)-n-(2-hydroxyethyl)-2,4,6-triiodoanilino]-3-oxopropanoyl]-(2-hydroxyethyl)amino]-1-n,3-n-bis(1,3-dihydroxypropan-2-yl)-2,4,6-triiodobenzene-1,3-dicarboxamide Chemical compound IC=1C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C(I)C=1N(CCO)C(=O)CC(=O)N(CCO)C1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I RHISTIGVAKTTCM-UHFFFAOYSA-N 0.000 claims 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 108010071289 Factor XIII Proteins 0.000 claims 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 claims 1
- 102100037362 Fibronectin Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 229910052688 Gadolinium Inorganic materials 0.000 claims 1
- 102000002068 Glycopeptides Human genes 0.000 claims 1
- 108010015899 Glycopeptides Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- AMDBBAQNWSUWGN-UHFFFAOYSA-N Ioversol Chemical compound OCCN(C(=O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I AMDBBAQNWSUWGN-UHFFFAOYSA-N 0.000 claims 1
- 239000002616 MRI contrast agent Substances 0.000 claims 1
- BAQCROVBDNBEEB-UBYUBLNFSA-N Metrizamide Chemical compound CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C(=O)N[C@@H]2[C@H]([C@H](O)[C@@H](CO)OC2O)O)=C1I BAQCROVBDNBEEB-UBYUBLNFSA-N 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims 1
- 102000013275 Somatomedins Human genes 0.000 claims 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 1
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims 1
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 1
- YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 229910052797 bismuth Inorganic materials 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229910000019 calcium carbonate Inorganic materials 0.000 claims 1
- 229940041011 carbapenems Drugs 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 239000012829 chemotherapy agent Substances 0.000 claims 1
- 230000035602 clotting Effects 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 229960005423 diatrizoate Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940012444 factor xiii Drugs 0.000 claims 1
- UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 claims 1
- 238000001879 gelation Methods 0.000 claims 1
- 239000003349 gelling agent Substances 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 150000004676 glycans Chemical class 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 239000011630 iodine Substances 0.000 claims 1
- 229910052740 iodine Inorganic materials 0.000 claims 1
- 229960004359 iodixanol Drugs 0.000 claims 1
- NBQNWMBBSKPBAY-UHFFFAOYSA-N iodixanol Chemical compound IC=1C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C(I)C=1N(C(=O)C)CC(O)CN(C(C)=O)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NBQNWMBBSKPBAY-UHFFFAOYSA-N 0.000 claims 1
- 229960001025 iohexol Drugs 0.000 claims 1
- NTHXOOBQLCIOLC-UHFFFAOYSA-N iohexol Chemical compound OCC(O)CN(C(=O)C)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I NTHXOOBQLCIOLC-UHFFFAOYSA-N 0.000 claims 1
- 229960004647 iopamidol Drugs 0.000 claims 1
- XQZXYNRDCRIARQ-LURJTMIESA-N iopamidol Chemical compound C[C@H](O)C(=O)NC1=C(I)C(C(=O)NC(CO)CO)=C(I)C(C(=O)NC(CO)CO)=C1I XQZXYNRDCRIARQ-LURJTMIESA-N 0.000 claims 1
- 229960002603 iopromide Drugs 0.000 claims 1
- DGAIEPBNLOQYER-UHFFFAOYSA-N iopromide Chemical compound COCC(=O)NC1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)N(C)CC(O)CO)=C1I DGAIEPBNLOQYER-UHFFFAOYSA-N 0.000 claims 1
- 229960004537 ioversol Drugs 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 229960000554 metrizamide Drugs 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 229940041009 monobactams Drugs 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 150000002960 penicillins Chemical class 0.000 claims 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims 1
- 239000002831 pharmacologic agent Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 229910052761 rare earth metal Inorganic materials 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 claims 1
- 235000019731 tricalcium phosphate Nutrition 0.000 claims 1
- 229940078499 tricalcium phosphate Drugs 0.000 claims 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims 1
- 239000002550 vasoactive agent Substances 0.000 claims 1
- 239000005526 vasoconstrictor agent Substances 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 102000009123 Fibrin Human genes 0.000 abstract 2
- 108010073385 Fibrin Proteins 0.000 abstract 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 2
- 229950003499 fibrin Drugs 0.000 abstract 2
- 229920001971 elastomer Polymers 0.000 abstract 1
- 239000000806 elastomer Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/225—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
- A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/502—Plasticizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Composite Materials (AREA)
- Materials Engineering (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Botany (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Compositions Of Macromolecular Compounds (AREA)
Abstract
Injektabilna smjesa koja se koristi za lumen mekog tkiva ili punilo za praznine u mekom tkivu, naznačena time, da ta smjesa sadrži: komponentu (a) koja sadrži fibrinogen, komponentu (b) koja sadrži trombin ili sredstvo koje potiče geliranje ili sredstvom za zgrušavanje za komponentu (a), komponentu (c) koja Sadrži najmanje jedan plastifikator i komponentu (d) koja sadrži mikročestice s prosječnim promjerom čestice između 0,01 - 200 pm, pri čemu se količina mikročestica kreće u rasponu od 10 do 45 % t/t ukupne smjese. Patent sadrži još 17 patentnih zahtjeva.
Claims (18)
1. Injektabilna smjesa koja se koristi za lumen mekog tkiva ili punilo za praznine u mekom tkivu, naznačena time, da ta smjesa sadrži: komponentu (a) koja sadrži fibrinogen, komponentu (b) koja sadrži trombin ili sredstvo koje potiče geliranje ili sredstvom za zgrušavanje za komponentu (a), komponentu (c) koja Sadrži najmanje jedan plastifikator i komponentu (d) koja sadrži mikročestice s prosječnim promjerom čestice između 0,01 - 200 pm, pri čemu se količina mikročestica kreće u rasponu od 10 do 45 % t/t ukupne smjese.
2. Smjesa iz patentnog zahtjeva 1, naznačena time, da su mikročestice takve mikročestice koje sadrže kalcij.
3. Smjesa iz patentnih zahtjeva 1 ili 2, naznačena time, da dodatno sadrži rendgensko kontrastno sredstvo.
4. Smjesa iz patentnih zahtjeva 1 ili 2, naznačena time, da dodatno sadrži kontrastno sredstvo odabrano iz skupine koju čine: rendgenska kontrastna sredstva, CT kontrastna sredstva i MRI kontrastna sredstva.
5. Smjesa iz patentnog zahtjeva 1, 2, 3 ili 4, naznačena time, da dodatno sadrži dodatnu komponentu odabranu iz skupine koju čine: čimbenici rasta, kemoterapijska sredstva, farmakološka sredstva i biološki djelatna sredstva poput antibiotika, odabranih iz skupine koju čine: aminoglikozidi, karbacefemi, karbapenemi, cefalosporini, glikopeptidi, marolidi, mono-baktami, penicilini, polipeptidi, sulfonamidi i tetraciklidi topljivi u vodi kao i u organskim otapalima, a osobito partikularno/koloidno srebro ili bizmut tioli; čimbenici rasta i biološki djelatna sredstva, odabrana iz skupine koju čine: epidermalni čimbenik rasta (EGF), transformirajući čimbenik rasta-alfa (TGF-[alfa]), transformirajući čimbenik rasta-beta (TGF-[beta]), čimbenik rasta stanica humanog endotela (ECGF), faktor stimulacije kolonija granulocitnih makrofaga (GM-CSF), koštani morfogenetski protein (BMP), čimbenik rasta živca (NGF), čimbenik rasta vaskularnog endotela (VEGF), čimbenik rasta fibroblasta (FGF), čimbenik rasta nalik inzulinu (IGF), i/ili čimbenik rasta izveden iz trombocita (PDGF); terapijska sredstva odabrana iz skupine koju čine: citotoksini, protutijela, analgetici, antikoagulansi, protuupalni spojevi, antimikrobne smjese, citokini, interferoni, hormoni, lipidi, demineralizirani koštani proteini, čimbenici poticanja rasta hrskavice, oligonukleotidi, polimeri, polisaharidi, polipeptidi, inhibitori proteaze, vazokonstriktori, vazodilatori, vitamin i minerali, vazoaktivna sredstva, neuroaktivna sredstva, anestetici, relaksanti mišića, steroidi, antikoagulansi, protuupalna sredstva, antiproliferacijska sredstva, antiulcerozna sredstva, antivirusna sredstva, imunomodulacijska sredstva, citotoksična sredstva, profilaktička sredstva, antigeni i protutijela.
6. Smjesa iz patentnih zahtjeva 1 i 5, naznačena time, da dodatna komponenta može biti sadržana bilo u fibrinogenu, trombinu ili sredstvu koje potiče geliranje ili sredstvu za poticanje zgrušavanja za komponentu (a), plastifikator ili mikročestice.
7. Smjesa iz patentnog zahtjeva 1, naznačena time, da fibrinogena komponenta sadrži jedan ili više sljedećih proteina odabranih iz skupine koju čine: fibronektin i plazma derivirani proteini.
8. Smjesa iz patentnog zahtjeva 1, naznačena time, da fibrinogena komponenta sadrži najmanje jedan protein odabran iz skupine koju čine: Faktor XIII, proteaze, inhibitori proteaze ili njihove smjese.
9. Smjesa iz patentnih zahtjeva 1 ili 2, naznačena time, da komponenta (b) sadrži mikročestice.
10. Smjesa iz patentnog zahtjeva 9, naznačena time, da su mikročestice takve mikročestice koje sadrže kalcijev fosfat.
11. Smjesa iz patentnih zahtjeva 1, 2 ili 9, naznačena time, da je kontrastno sredstvo organski spoj koji sadrži jod.
12. Smjesa iz patentnog zahtjeva 11, naznačena time, da organski spoj sadrži element rijetke zemlje, poželjno je gadolinij.
13. Smjesa iz patentnih zahtjeva 3 ili 11, naznačena time, da je kontrastno sredstvo odabrano iz skupine koju čine: diatrizoat, jodekol, jodiksanol, jofratol, jogulamid, joheksol, jomeprol, jopamidol, jopromid, jotrol, joversol, joksagulat i metrizamid te njihove smjese.
14. Smjesa iz patentnog zahtjeva 1, naznačena time, da količina plastifikatora u smjesi iznosi od 10 - 80 % konačnog pripravka, poželjno je od 15 - 60 % t/v konačnog pripravka, poželjnije od 20 - 40 % t/v konačnog pripravka.
15. Smjesa iz patentnog zahtjeva 2, naznačena time, da je čestica koja sadrži kalcij odabrana iz skupine koju čine: trikalcijev fosfat, alfa trikalcijev fosfat, beta trikalcijev fosfat, kalcijev fosfat, polimorf kalcijevog fosfata, hidroksiapatit, kalcijev karbonat, kalcijev sulfat, alfa trikalcijev fosfat, beta trikalcijev fosfat i njihove smjese.
16. Smjesa iz patentnog zahtjeva 1 ili 2, naznačena time, da mikročestice imaju prosječni promjer od 0,01 µm - 100 µm, poželjno je od 0,01 µm - 50 µm.
17. Smjesa iz patentnog zahtjeva 1 ili 2, naznačena time, da je težina mikročestica u rasponu od 30 - 40 % t/t ukupne smjese.
18. Smjesa iz patentnog zahtjeva 1, naznačena time, da je količina fibrinogena u smjesi u rasponu od 10 - 200 mg/ml, poželjno je 25 mg/ml - 50 mg/ml.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92004307P | 2007-03-26 | 2007-03-26 | |
PCT/US2008/058146 WO2008118913A2 (en) | 2007-03-26 | 2008-03-25 | Injectable void filler for soft tissue augmentation |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120092T1 true HRP20120092T1 (hr) | 2012-02-29 |
Family
ID=39560923
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120092T HRP20120092T1 (hr) | 2007-03-26 | 2012-01-26 | Injektibilna smjesa za lumen mekog tkiva |
Country Status (17)
Country | Link |
---|---|
US (3) | US20080241072A1 (hr) |
EP (1) | EP2136852B1 (hr) |
JP (2) | JP5385257B2 (hr) |
KR (1) | KR101512863B1 (hr) |
CN (1) | CN101678151B (hr) |
AT (1) | ATE542552T1 (hr) |
AU (1) | AU2008230916B2 (hr) |
BR (1) | BRPI0809383B8 (hr) |
CA (1) | CA2682034C (hr) |
CO (1) | CO6241133A2 (hr) |
DK (1) | DK2136852T3 (hr) |
ES (1) | ES2381448T3 (hr) |
HR (1) | HRP20120092T1 (hr) |
MX (1) | MX2009010387A (hr) |
PL (1) | PL2136852T3 (hr) |
PT (1) | PT2136852E (hr) |
WO (1) | WO2008118913A2 (hr) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE494916T1 (de) * | 2006-05-26 | 2011-01-15 | Baxter Int | Injizierbarer füllstoff für knochenhohlräume |
US9421302B2 (en) | 2006-05-26 | 2016-08-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
US8143722B2 (en) | 2006-10-05 | 2012-03-27 | Flipchip International, Llc | Wafer-level interconnect for high mechanical reliability applications |
KR101512863B1 (ko) | 2007-03-26 | 2015-04-16 | 백스터 인터내셔널 인코포레이티드 | 주입 가능한 연조직 증강용 공극 충전제 |
US20100331254A1 (en) * | 2007-12-26 | 2010-12-30 | Metamorefix | Pulverized fibrin clots and pharmaceutical compositions containing them |
US8678008B2 (en) | 2008-07-30 | 2014-03-25 | Ethicon, Inc | Methods and devices for forming an auxiliary airway for treating obstructive sleep apnea |
US8556797B2 (en) | 2008-07-31 | 2013-10-15 | Ethicon, Inc. | Magnetic implants for treating obstructive sleep apnea and methods therefor |
US8413661B2 (en) | 2008-08-14 | 2013-04-09 | Ethicon, Inc. | Methods and devices for treatment of obstructive sleep apnea |
US8561616B2 (en) | 2008-10-24 | 2013-10-22 | Ethicon, Inc. | Methods and devices for the indirect displacement of the hyoid bone for treating obstructive sleep apnea |
US8561617B2 (en) | 2008-10-30 | 2013-10-22 | Ethicon, Inc. | Implant systems and methods for treating obstructive sleep apnea |
US8783258B2 (en) | 2008-12-01 | 2014-07-22 | Ethicon, Inc. | Implant systems and methods for treating obstructive sleep apnea |
US8800567B2 (en) | 2008-12-01 | 2014-08-12 | Ethicon, Inc. | Implant systems and methods for treating obstructive sleep apnea |
US8307831B2 (en) | 2009-03-16 | 2012-11-13 | Ethicon, Inc. | Implant systems and methods for treating obstructive sleep apnea |
AU2010252929B2 (en) * | 2009-05-28 | 2015-08-27 | Mallinckrodt Pharma Ip Trading D.A.C. | Dry powder fibrin sealant |
US9326886B2 (en) | 2009-10-29 | 2016-05-03 | Ethicon, Inc. | Fluid filled implants for treating obstructive sleep apnea |
US9877862B2 (en) | 2009-10-29 | 2018-01-30 | Ethicon, Inc. | Tongue suspension system with hyoid-extender for treating obstructive sleep apnea |
US9974683B2 (en) | 2009-10-30 | 2018-05-22 | Ethicon, Inc. | Flexible implants having internal volume shifting capabilities for treating obstructive sleep apnea |
US8632488B2 (en) | 2009-12-15 | 2014-01-21 | Ethicon, Inc. | Fluid filled implants for treating medical conditions |
SA111320355B1 (ar) | 2010-04-07 | 2015-01-08 | Baxter Heathcare S A | إسفنجة لايقاف النزف |
CA2840546C (en) * | 2010-06-28 | 2020-05-05 | Bbs-Bioactive Bone Substitutes Oy | A method for preparing a bone protein preparation and a bone protein preparation containing polyethylene glycol/glycerol matrix and calcium salt granules |
US8637067B1 (en) * | 2011-03-10 | 2014-01-28 | Lifecell Corporation | Elastic tissue matrix derived hydrogel |
US8905033B2 (en) | 2011-09-28 | 2014-12-09 | Ethicon, Inc. | Modular tissue securement systems |
US9161855B2 (en) | 2011-10-24 | 2015-10-20 | Ethicon, Inc. | Tissue supporting device and method |
US8973582B2 (en) | 2011-11-30 | 2015-03-10 | Ethicon, Inc. | Tongue suspension device and method |
US10470760B2 (en) | 2011-12-08 | 2019-11-12 | Ethicon, Inc. | Modified tissue securement fibers |
AU2013232380A1 (en) | 2012-03-12 | 2014-09-25 | The Regents Of The University Of California | Methods and compositions for treating wounds and reducing the risk of incisional hernias |
US9173766B2 (en) | 2012-06-01 | 2015-11-03 | Ethicon, Inc. | Systems and methods to treat upper pharyngeal airway of obstructive sleep apnea patients |
EP3473276B1 (en) * | 2012-10-18 | 2023-12-13 | Mayo Foundation for Medical Education and Research | Techniques for treatment of abscesses |
US20160303281A1 (en) | 2015-04-17 | 2016-10-20 | Rochal Industries, Llc | Composition and kits for pseudoplastic microgel matrices |
WO2017079328A1 (en) * | 2015-11-02 | 2017-05-11 | Nanofiber Solutions, Inc. | Electrospun fibers having contrast agents and methods of making the same |
AU2018277198B2 (en) * | 2017-05-30 | 2023-08-31 | Aqpha Ip B.V | Resorbable biodegradable medical and cosmetic composition comprising poly(1,3-trimethylene carbonate) |
CA3075099A1 (en) * | 2017-10-18 | 2019-04-25 | Lifecell Corporation | Adipose tissue products and methods of production |
US11826488B2 (en) | 2017-10-19 | 2023-11-28 | Lifecell Corporation | Flowable acellular tissue matrix products and methods of production |
CN114409734B (zh) * | 2022-01-25 | 2023-05-12 | 四川大学华西医院 | 一种可诱导局部麻醉药生物矿化的自组装短肽及其制得的长效局部麻醉和镇痛药物制剂 |
CN114573660B (zh) * | 2022-03-15 | 2023-06-13 | 四川大学华西医院 | 一种自组装短肽及其诱导局部麻醉药生物矿化制得的长效局部麻醉和镇痛药物制剂 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0166263A1 (en) | 1984-05-31 | 1986-01-02 | Green Cross Corporation | Filler composition for filling in defect or hollow portion of bone and kit or set for the preparation of the filler composition |
US4696812A (en) * | 1985-10-28 | 1987-09-29 | Warner-Lambert Company | Thrombin preparations |
GB8916781D0 (en) | 1989-07-21 | 1989-09-06 | Nycomed As | Compositions |
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
FR2715853B1 (fr) | 1994-02-08 | 1996-04-26 | Centre Nat Rech Scient | Composition pour bio-matériau; procédé de préparation. |
US6287341B1 (en) | 1995-05-19 | 2001-09-11 | Etex Corporation | Orthopedic and dental ceramic implants |
US5702715A (en) * | 1995-10-27 | 1997-12-30 | Drying Technology | Reinforced biological sealants |
US5752974A (en) * | 1995-12-18 | 1998-05-19 | Collagen Corporation | Injectable or implantable biomaterials for filling or blocking lumens and voids of the body |
US5782917A (en) * | 1996-02-26 | 1998-07-21 | Sunmed, Inc. | Intramedullary bone plug |
US20010016646A1 (en) * | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
US7041641B2 (en) * | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
JP2002514960A (ja) * | 1997-06-18 | 2002-05-21 | コヘージョン テクノロジーズ,インコーポレイテッド | トロンビンおよびミクロフィブリルコラーゲンを含む組成物、ならびにその調製および使用の方法 |
WO2000007639A1 (en) | 1998-08-07 | 2000-02-17 | Tissue Engineering, Inc. | Bone precursor compositions |
US6605294B2 (en) * | 1998-08-14 | 2003-08-12 | Incept Llc | Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels |
US6607535B1 (en) * | 1999-02-04 | 2003-08-19 | Kwan-Ho Chan | Universal bone cement plug and method of use |
DE19956503A1 (de) | 1999-11-24 | 2001-06-21 | Universitaetsklinikum Freiburg | Spritzbares Knochenersatzmaterial |
SE517168C2 (sv) | 2000-07-17 | 2002-04-23 | Bone Support Ab | En komposition för ett injicerbart ersättningsmaterial för benmineral |
US20050136038A1 (en) | 2001-10-02 | 2005-06-23 | Isotis N.V. | Injectable calcium salt bone filler comprising cells |
SE522098C2 (sv) * | 2001-12-20 | 2004-01-13 | Bone Support Ab | Ett nytt benmineralsubstitut |
CA2470597C (en) | 2001-12-20 | 2013-05-28 | Bone Support Ab | Artificial bone mineral substitute material containing a ceramic and a water soluble non-ionic x-ray contrast agent |
US7341716B2 (en) * | 2002-04-12 | 2008-03-11 | Boston Scientific Scimed, Inc. | Occlusive composition |
US7135027B2 (en) * | 2002-10-04 | 2006-11-14 | Baxter International, Inc. | Devices and methods for mixing and extruding medically useful compositions |
US20050220882A1 (en) | 2004-03-04 | 2005-10-06 | Wilson Pritchard | Materials for medical implants and occlusive devices |
US7621952B2 (en) | 2004-06-07 | 2009-11-24 | Dfine, Inc. | Implants and methods for treating bone |
WO2006072622A2 (en) | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
WO2006073711A2 (en) * | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
US9421302B2 (en) | 2006-05-26 | 2016-08-23 | Baxter International Inc. | Injectable fibrin composition for bone augmentation |
ATE494916T1 (de) * | 2006-05-26 | 2011-01-15 | Baxter Int | Injizierbarer füllstoff für knochenhohlräume |
KR101512863B1 (ko) | 2007-03-26 | 2015-04-16 | 백스터 인터내셔널 인코포레이티드 | 주입 가능한 연조직 증강용 공극 충전제 |
-
2008
- 2008-03-25 KR KR1020097022201A patent/KR101512863B1/ko active IP Right Grant
- 2008-03-25 BR BRPI0809383A patent/BRPI0809383B8/pt not_active IP Right Cessation
- 2008-03-25 CN CN200880016687.0A patent/CN101678151B/zh not_active Expired - Fee Related
- 2008-03-25 CA CA2682034A patent/CA2682034C/en active Active
- 2008-03-25 PT PT08744335T patent/PT2136852E/pt unknown
- 2008-03-25 PL PL08744335T patent/PL2136852T3/pl unknown
- 2008-03-25 WO PCT/US2008/058146 patent/WO2008118913A2/en active Application Filing
- 2008-03-25 AT AT08744335T patent/ATE542552T1/de active
- 2008-03-25 AU AU2008230916A patent/AU2008230916B2/en not_active Ceased
- 2008-03-25 EP EP08744335A patent/EP2136852B1/en active Active
- 2008-03-25 ES ES08744335T patent/ES2381448T3/es active Active
- 2008-03-25 DK DK08744335.4T patent/DK2136852T3/da active
- 2008-03-25 MX MX2009010387A patent/MX2009010387A/es active IP Right Grant
- 2008-03-25 JP JP2010501164A patent/JP5385257B2/ja not_active Expired - Fee Related
- 2008-03-25 US US12/054,990 patent/US20080241072A1/en not_active Abandoned
-
2009
- 2009-10-26 CO CO09120181A patent/CO6241133A2/es not_active Application Discontinuation
-
2011
- 2011-01-11 US US13/004,179 patent/US8377420B2/en active Active
-
2012
- 2012-01-26 HR HR20120092T patent/HRP20120092T1/hr unknown
-
2013
- 2013-01-10 US US13/738,400 patent/US9278160B2/en active Active
- 2013-04-17 JP JP2013086302A patent/JP2013138947A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
DK2136852T3 (da) | 2012-04-16 |
CO6241133A2 (es) | 2011-01-20 |
US9278160B2 (en) | 2016-03-08 |
JP2010522617A (ja) | 2010-07-08 |
CN101678151A (zh) | 2010-03-24 |
WO2008118913A3 (en) | 2009-12-03 |
PL2136852T3 (pl) | 2012-07-31 |
ATE542552T1 (de) | 2012-02-15 |
CA2682034A1 (en) | 2008-10-02 |
CA2682034C (en) | 2015-01-27 |
US20110117027A1 (en) | 2011-05-19 |
KR101512863B1 (ko) | 2015-04-16 |
AU2008230916B2 (en) | 2013-10-03 |
BRPI0809383A2 (pt) | 2014-09-09 |
MX2009010387A (es) | 2009-10-19 |
US20130209370A1 (en) | 2013-08-15 |
WO2008118913A2 (en) | 2008-10-02 |
JP5385257B2 (ja) | 2014-01-08 |
EP2136852B1 (en) | 2012-01-25 |
EP2136852A2 (en) | 2009-12-30 |
AU2008230916A1 (en) | 2008-10-02 |
US8377420B2 (en) | 2013-02-19 |
CN101678151B (zh) | 2014-04-16 |
US20080241072A1 (en) | 2008-10-02 |
KR20090122492A (ko) | 2009-11-30 |
JP2013138947A (ja) | 2013-07-18 |
PT2136852E (pt) | 2012-02-08 |
BRPI0809383B1 (pt) | 2018-10-30 |
ES2381448T3 (es) | 2012-05-28 |
BRPI0809383B8 (pt) | 2021-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120092T1 (hr) | Injektibilna smjesa za lumen mekog tkiva | |
US9125966B2 (en) | Bone repair material | |
JP2010522617A5 (hr) | ||
Verron et al. | Controlling the biological function of calcium phosphate bone substitutes with drugs | |
CA2518104C (en) | Artificial bone mineral substitute for in vivo hardening | |
DE102006042142A1 (de) | Phasen- und sedimentationsstabile, plastisch verformbare Zubereitung mit intrinsischer Porenbildung, bspw. zum Auffüllen von Knochendefekten bzw. zur Verwendung als Knochenersatzmaterial, und Verfahren zu deren Herstellung | |
KR20080096746A (ko) | 골 재생을 위한 2상 시멘트 전구체 시스템 | |
KR102066777B1 (ko) | 생체주입형 산소 방출 하이드로젤의 제조 방법 및 이의 생의학적 용도 | |
Sheng et al. | Advanced applications of strontium-containing biomaterials in bone tissue engineering | |
Moussi et al. | Injectable macromolecule-based calcium phosphate bone substitutes | |
DE202006013761U1 (de) | Phasen- und sedimentationsstabile, plastisch verformbare Zubereitung mit intrinsischer Porenbildung, bspw. zum Auffüllen von Knochendefekten bzw. zur Verwendung als Knochenersatzmaterial | |
Qu et al. | Drug-loading calcium phosphate cements for medical applications | |
Lodoso Torrecilla | Fine-Tuning the Degradation and Biological Properties of Calcium Phosphate Cements | |
Chen | Materiobiological Effects Regulate the Bone Microenvironment | |
Tian et al. | A novel bioactive and degradable magnesium screw with polymer coating developed for osteoporotic fracture fixation | |
AU2014200027B2 (en) | Injectable void filler for soft tissue augmentation |